Skip to main content
editorial
. 2022 Sep 26;23(19):11363. doi: 10.3390/ijms231911363

Figure 1.

Figure 1

Schematic figure representing the synergistic activity of immune-based combinations (including double checkpoint blockade and immune checkpoint inhibitors plus antiangiogenic agents.